{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:16:34Z","timestamp":1777853794365,"version":"3.51.4"},"reference-count":33,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Intensive Care Med"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:p>Background: Ondansetron is a preferred anti-emetic in critical care to treat nausea and vomiting, and has historically been considered a largely safe option. A recent pharmacoepidemiology study reported that ondansetron may be associated with an increased risk for acute kidney injury (AKI). Methods: We interrogated the High-Density Intensive Care (HiDenIC-15) database containing intensive care data for 13 hospitals across Western Pennsylvania between Oct 2008-Dec 2014. AKI was defined using the Kidney Disease, Improving Global Outcomes 2012 guidelines. Ondansetron use was considered as receiving any form of ondansetron within 24\u2005h of admission. The subsequent 48\u2005h (hours 25-72 after admission) were analyzed for outcomes. Primary outcome was development of AKI; secondary outcomes included 90-day mortality and time to AKI. Propensity-matched, multivariate logistic regression was applied for both outcomes. Comparator groups were metoclopramide and prochlorperazine using the same exposure criteria. Results:AKI occurred in 965 (5.6%), 12 (3.0%), and 61 (6.5%) patients receiving ondansetron, prochlorperazine, and metoclopramide, respectively. In the adjusted analysis, no anti-emetic was associated with a significant change in the odds of developing AKI. Ondansetron was associated with a 5.48% decrease (CI \u22126.17\u2013\u22124.79) in death within 90 days of ICU-admission, which was independent of AKI status; an effect not seen with other anti-emetics. Anti-emetic usage was not associated with a change in the time to first AKI. Conclusion:Anti-emetic usage did not alter AKI risk. Ondansetron was associated with a significant decrease in 90-day mortality that was not seen by other anti-emetics, which requires further exploration.<\/jats:p>","DOI":"10.1177\/08850666211073582","type":"journal-article","created":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T08:07:51Z","timestamp":1641629271000},"page":"1403-1410","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Kidney and Mortality Outcomes Associated with Ondansetron in Critically Ill Patients"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1838-6215","authenticated-orcid":false,"given":"Matthew","family":"Gray","sequence":"first","affiliation":[{"name":"University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA"},{"name":"Center for Critical Care Nephrology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Priyanka","sequence":"additional","affiliation":[{"name":"Center for Critical Care Nephrology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Kane-Gill","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA"},{"name":"Center for Critical Care Nephrology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lirong","family":"Wang","sequence":"additional","affiliation":[{"name":"Computational Chemical Genomics Screening Center, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Kellum","sequence":"additional","affiliation":[{"name":"Center for Critical Care Nephrology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,1,8]]},"reference":[{"key":"bibr1-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001485"},{"key":"bibr2-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X15618131"},{"key":"bibr3-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1111\/anae.15295"},{"key":"bibr4-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000004833"},{"key":"bibr5-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4789"},{"key":"bibr6-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2009.09.028"},{"key":"bibr7-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2014.03.017"},{"key":"bibr8-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.1080688"},{"key":"bibr9-08850666211073582","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2020.011"},{"key":"bibr10-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.6.6.685"},{"key":"bibr11-08850666211073582","doi-asserted-by":"publisher","DOI":"10.4037\/NCI.0b013e3182248a2b"},{"key":"bibr12-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98734-x"},{"issue":"3","key":"bibr13-08850666211073582","first-page":"18","volume":"79","author":"Zaitseva EN","year":"2016","journal-title":"Eksp Klin Farmakol"},{"key":"bibr14-08850666211073582","volume-title":"Metoclopramide Hydrochloride Inravenous, Intramuscular Injection","author":"Product Information","year":"2016"},{"key":"bibr15-08850666211073582","volume-title":"ZOFRAN(R) Intravenous Injection, Ondansetron Hydrochloride Intravenous Injection","author":"Product Information","year":"2012"},{"key":"bibr16-08850666211073582","volume-title":"Prochlorperazine Maleate Oral Tablets, Prochlorperazine Oral Tablets","author":"Product Information","year":"2011"},{"key":"bibr17-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32563-2"},{"key":"bibr18-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017070765"},{"key":"bibr19-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-015-3934-7"},{"key":"bibr20-08850666211073582","doi-asserted-by":"publisher","DOI":"10.12788\/jhm.2683"},{"key":"bibr21-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296"},{"issue":"1","key":"bibr22-08850666211073582","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Levin A","year":"2013","journal-title":"Kidney Int Suppl (2011)."},{"key":"bibr23-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31819def97"},{"key":"bibr24-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1378\/chest.100.6.1619"},{"key":"bibr25-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.2008.01586.x"},{"key":"bibr26-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1186\/cc11454"},{"key":"bibr27-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"bibr28-08850666211073582","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00650117"},{"key":"bibr29-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6607"},{"key":"bibr30-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4960"},{"key":"bibr31-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106158"},{"key":"bibr32-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1119(03)00503-1"},{"key":"bibr33-08850666211073582","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.21554"}],"container-title":["Journal of Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08850666211073582","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08850666211073582","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08850666211073582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:57:05Z","timestamp":1777503425000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08850666211073582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,8]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1177\/08850666211073582"],"URL":"https:\/\/doi.org\/10.1177\/08850666211073582","relation":{},"ISSN":["0885-0666","1525-1489"],"issn-type":[{"value":"0885-0666","type":"print"},{"value":"1525-1489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,8]]}}}